Glaukos Corp (GKOS) Stock AnalysisGKOSStock AnalysisGlaukos Corp

Glaukos Corporation is an ophthalmic pharmaceutical and medical technology company. The Company is focused on developing and commercializing therapies for the treatment of glaucoma, corneal disorders and retinal diseases. Its commercial solutions and development-stage product candidates include procedural pharmaceuticals based on an intracameral drug delivery technology designed to reduce intraocular pressure (IOP) by delivering therapeutic levels of glaucoma medication from inside the eye over an extended period of time; Micro-Invasive Glaucoma Surgery (MIGS) products that primarily involve the insertion of a micro-scale device designed to reduce IOP by restoring the natural aqueous humor outflow pathways for patients suffering from glaucoma; bio-activated pharmaceuticals that are intended to strengthen, stabilize, and reshape the cornea for patients impacted by corneal ectatic disorders such as keratoconus, among others. It operates in the Healthcare sector (SURGICAL & MEDICAL INSTRUMENTS & APPARATUS industry).

Glaukos Corp (GKOS) is currently priced at $179.87, which is below the average analyst price target of $202, indicating potential upside. However, the RSI is at 40.55, suggesting it is approaching oversold territory, but not yet a strong buy signal. The company has shown strong revenue growth, with Q2 2026 revenue at $185.6 million, a 50% year-over-year increase, but it still faces significant net losses, with a net income of -$18.4 million in Q2 2026. The recent insider selling of 60,000 shares raises concerns about future performance, which is a notable risk. Overall, while there are positive growth indicators, the risks associated with insider selling and ongoing losses suggest a cautious approach, hence a hold recommendation.

10 analysts cover GKOS: 10 rate it Buy, 0 Hold and 0 Sell. The average price target is 127.08.